Results 101 to 110 of about 73,193 (159)

Association of Venous Thromboembolism Risk with Atopic Dermatitis and Janus Kinase Inhibitors Treatment: A Mendelian Randomization Study. [PDF]

Clin Appl Thromb Hemost
Chen Z, Wang S, Wang Y.
europepmc   +1 more source

Progression of mycosis fungoides in a patient receiving a Janus kinase inhibitor. [PDF]

JAAD Case Rep
Stankiewicz JM, Kersten JM, Merkus VA, de Haan S, Jansen PM, Vermeer MH, Ottevanger R.   +6 more
europepmc   +1 more source

Real-world comparative effectiveness of sarilumab versus Janus kinase inhibitors as monotherapy in rheumatoid arthritis. [PDF]

Arthritis Res Ther
Nozaki Y, Kishimoto K, Itami T, Tomita D, Wada Y, Kotani T, Takeuchi T, Hidaka T, Hino S, Miyamoto T, Miyake H, Hatta K, Mamoto K, Yamada Y, Okano T, Okano T, Saegusa J, Horita M, Nishida K, Kinoshita K, Rai S.   +20 more
europepmc   +1 more source

Optimizing Janus kinase inhibitor therapy for ulcerative colitis: a real-world perspective. [PDF]

Intest Res
Akiyama S.
europepmc   +1 more source

Intraocular infections following biologicals and Janus Kinase inhibitors. [PDF]

Indian J Ophthalmol
Dutta Majumder P, Kene RD.
europepmc   +1 more source

Janus kinase inhibitors in pulmonary and extra-pulmonary sarcoidosis: A case series and a systematic review of the literature. [PDF]

Sarcoidosis Vasc Diffuse Lung Dis
Quaggetto M, Ben Salem T, Haroche J, Campagne J, Moyon Q, Lhote R, Amoura Z, Cohen Aubart F.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis

Cochrane Database of Systematic Reviews, 2015
Myelofibrosis is a bone marrow disorder characterized by excessive production of reticulin and collagen fiber deposition caused by hematological and non-hematological disorders. The prognosis of myelofibrosis is poor and treatment is mainly palliative.
Arturo J, Martí-Carvajal, Vidhu, Anand, Ivan, Solà   +2 more
openaire   +4 more sources

Janus Kinase Mutations

Seminars in Oncology, 2009
The chronic myeloproliferative neoplasms (MPNs) polycythemia vera (PV), essential thrombocytosis (ET), and primary myelofibrosis (MF) are commonly associated with mutations in the Janus kinase gene JAK2. A hallmark of PV is an abundance of red blood cells; ET, too many platelets; and MF, accumulation of neutrophils and monocytes accompanied by bone ...
openaire   +2 more sources

The many faces of Janus kinase

Biochemical Pharmacology, 2012
Janus kinases have proved to be essential for many immunological processes but there is growing evidence that they also play a critical role in pathogenesis of many diseases including inflammatory diseases and cancer where they promote multiple steps of tumorigenesis.
Matthew M, Seavey, Pawel, Dobrzanski
openaire   +2 more sources

Negative Regulation of Janus Kinases

Cell Biochemistry and Biophysics, 2001
The precise regulation of both the magnitude and the duration of Janus kinase (JAK) catalytic activity is essential for the cytokine orchestration of many biological processes, and the dysregulation of JAK activity has pathological implications.
R J, Duhé, L H, Wang, W L, Farrar
openaire   +2 more sources